CCF642

• CAT Number: I003269
• CAS Number: 346640-08-2
• Molecular Formula: C15H10N2O4S3
• Molecular Weight: 378.45
• Purity: ≥95%
• Target: Metabolic Enzyme/Protease
• Solubility: DMSO ≥ 30 mg/mL
• Storage: Store at -20°C
• IUPAC Name: (5E)-3-(4-methoxyphenyl)-5-[(5-nitrothiophen-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• InChI: InChI=1S/C15H10N2O4S3/c1-21-10-4-2-9(3-5-10)16-14(18)12(24-15(16)22)8-11-6-7-13(23-11)17(19)20/h2-8H,1H3/b12-8+
• InChIKey: SPYIETQLOVDJCF-XYOKQWHBSA-N
• SMILES: O=C1N(C2=CC=C(OC)C=C2)C(S/C1=C/C3=CC=C([N+]([O-])=O)S3)=S

CCF642(CAT: I003269) is a novel protein disulfide isomerase (PDI) inhibitor with potent antimyeloma activity. It demonstrates an IC₅₀ of 2.9 μmol/L, making it approximately 100-fold more effective at inhibiting PDI reductase activity compared to established inhibitors like PACMA 31 and LOC14. In vitro, CCF642 induces acute endoplasmic reticulum (ER) stress in multiple myeloma cells, triggering apoptosis through calcium release. In vivo, CCF642 exhibits significant efficacy in a syngeneic mouse model of aggressive multiple myeloma, prolonging lifespan in C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma cells. Its therapeutic effect is comparable to bortezomib, a first-line treatment for multiple myeloma. CCF642 can be administered intravenously at 10 mg/kg without adverse injection reactions, highlighting its safety and potential for clinical development

Reference

[1]. Vatolin S et al. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
Cancer Res. 2016 Jun 1;76(11):3340-50.